Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 7/20 | 0.54 |
| ▸ | ERN1 | O75460 | 5/20 | 0.46 |
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5560733 | 0.81 | TNFRSF1A (0.57) | TNFRSF1AERN1RPS6KB2MAPTMEN1 | |
| SCHEMBL2780877 | 0.78 | RPS6KB2 (0.56) | TNFRSF1AERN1RPS6KB2MAPTMEN1 | |
| SCHEMBL6091643 | 0.76 | TNFRSF1A (0.59) | TNFRSF1AERN1MAPTMEN1KMT2A | |
| SCHEMBL5565309 | 0.75 | ERN1 (0.60) | TNFRSF1AERN1RPS6KB2MAPTMEN1 | |
| SCHEMBL26259904 | 0.74 | RPS6KB2 (0.56) | TNFRSF1AERN1RPS6KB2MAPTMEN1 | |
| SCHEMBL6040741 | 0.73 | ERN1 (0.61) | TNFRSF1AERN1RPS6KB2KDM4E | |
| SCHEMBL6040725 | 0.72 | ERN1 (0.50) | TNFRSF1AERN1RPS6KB2MAPTMEN1 | |
| SCHEMBL5571805 | 0.72 | TNFRSF1A (0.74) | TNFRSF1A | |
| SCHEMBL5576244 | 0.72 | TNFRSF1A (0.68) | TNFRSF1A | |
| SCHEMBL5571808 | 0.72 | TNFRSF1A (0.74) | TNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202247-B2 | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | ATHEROGENICS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20030232877-A1 | 1,3-Bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | CRABTREE ACQUISITION CO, LLC | 2003-12-18 | — | — | US | disclosed |
| WO-2003053359-A2 | 1,3-BIS-(SUBSTITUTED-PHENYL)-2-PROPYN-1-ONES AND THEIR USE TO TREAT DISORDERS | ATHEROGENICS, INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232877-A1 | 1,3-Bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | SLC10A1, PKD1, ABCB11 | TNFRSF1A 4867/4885ERN1 2413/4885RPS6KB2 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.